Drug Information
Drug General Information | Top | |||
---|---|---|---|---|
Drug ID |
D2EF8M
|
|||
Drug Name |
AZD0780
|
|||
Drug Type |
Small molecule
|
|||
Indication | Elevated Lipoprotein(a) [ICD-11: 5C80.1] | Phase 1 | [1] | |
Company |
AstraZeneca
|
Target and Pathway | Top | |||
---|---|---|---|---|
Target(s) | Proprotein convertase subtilisin/kexin type 9 (PCSK9) | Target Info | . | [2] |
WikiPathways | PCSK9-mediated LDLR degradation |
References | Top | |||
---|---|---|---|---|
REF 1 | ClinicalTrials.gov (NCT05384262) A Phase I, Randomized, Single-Blind, Placebo-controlled Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD0780 Following Single and Multiple Ascending Dose Administration to Healthy Subjects With or Without Elevated LDL-C Levels. U.S.National Institutes of Health. | |||
REF 2 | Clinical pipeline report, company report or official report of AstraZeneca |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.